Τόμος 16 (1998) – Τεύχος 2+2Σ – Άρθρο 5 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 16 (1998) – Issue 2+2Σ – Article 5 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Από | | Άρθρο - Article, Γεώργιος Ν. Καραχάλιος - George N. Karachalios, Ευσταθία Μ. Τζιβίσκου,E.M. Tziviskou, Πλήρες Κείμενο στα Ελληνικά - Full Text in Greek

 

Τίτλος – Title

Βανκομυκίνη: Είναι Αναγκαίος ο Προσδιορισμός της Συγκεντρώσεώς της στον Ορό;

Vancomycin: Is it Necessary the Therapeutic Drug Monitoring?
Συγγραφέας – Author

Γεώργιος Ν. Καραχάλιος και Ευσταθία Μ. Τζιβίσκου

Εργαστήριο Φυσιολογίας, Τμήμα Νοσηλευτικής, Πανεπιστήμιο Αθηνών

G.N. Karachalios and E.M. Tziviskou

Third Clinic of Internal Medicine, Hellenic Red Cross Hospital, Athens, Greece
Παραπομπή – Citation

Καραχάλιος,Γ.Ν.,Τζιβίσκου,Ε.Μ.  : Βανκομυκίνη: Είναι Αναγκαίος ο Προσδιορισμός της Συγκεντρώσεώς της στον Ορό; , Επιθεώρηση Κλιν. Φαρμακολ. Φαρμακοκινητ. 16 :  (1998)

Karachalios,G.N., Tziviskou,E.M. : Vancomycin: Is it Necessary the Therapeutic Drug Monitoring?, Epitheorese Klin. Farmakol. Farmakokinet. 16:  (1998)
Ημερομηνία Δημοσιευσης – Publication Date
–
Γλώσσα Πλήρους Κειμένου –
Full Text Language

Ελληνικά – Greek
Παραγγελία – Αγορά –
Order – Buy
Ηλεκτρονική Μορφή: pdf (15 €) –
Digital Type: pdf (15 €)
pharmakonpress[at]pharmakonpress[.]gr
Λέξεις κλειδιά – Keywords

Βανκομυκίνη, συγκεντρώσεις ορού, αναγκαιότητα

Vancomycin, serum concentrations, necessity
Λοιποί Όροι – Other Terms

Άρθρο

Article
Περίληψη – Summary

Στην εργασία αυτή α­να­σκο­πεί­ται η βι­βλιο­γρα­φί­α ό­σον α­φο­ρά τη χρη­σι­μό­τη­τα ή μη του προσ­διο­ρι­σμού της συ­γκε­ντρώ­σε­ως της βαν­κο­μυ­κί­νης του ο­ρού. Αν και η ε­μπει­ρί­α με τη χρή­ση της βαν­κο­μυ­κί­νης εί­ναι με­γα­λύ­τε­ρη των 40 ε­τών, εν τού­τοις ε­ξα­κο­λου­θούν να υ­πάρ­χουν αλ­λη­λο­συ­γκρου­ό­με­νες α­πό­ψεις κα­τά πό­σον οι συ­γκε­ντρώ­σεις της βαν­κο­μυ­κί­νης του ο­ρού συ­σχε­τί­ζο­νται στε­νώς με την κλι­νι­κή α­πο­τε­λε­σμα­τι­κό­τη­τα ή το­ξι­κό­τη­τά της. Όμως, υ­πάρ­χουν ει­δι­κές ο­μά­δες α­σθε­νών στους ο­ποί­ους κρί­νε­ται α­πα­ραί­τη­τος ο προσ­διο­ρι­σμός της συ­γκε­ντρώ­σε­ως της βαν­κο­μυ­κί­νης του ο­ρού, ό­πως εί­ναι α­σθε­νείς με νε­φρι­κή α­νε­πάρ­κει­α, νέ­οι και γέ­ρο­ντες α­σθε­νείς και α­σθε­νείς οι ο­ποί­οι λαμ­βά­νουν ταυ­το­χρό­νως νε­φρο­το­ξι­κά φάρ­μα­κα, ό­πως α­μι­νο­γλυ­κο­σί­δες, αμ­φο­τε­ρι­κί­νη Β κ.λπ.

Renewed interest in vancomycin over the past decade has led to an abundance of data concerning. The pharmacokinetics of van­comycin, and its dosage selection and concentra­tion-response and toxicity relationships. There is still skeptikism, about the relationship between serum vancomycin concentrations and clinical ef­ficacy or toxicity. Despite these limitations, recent data suggest that monitoring serum vancomycin concentrations will be adjust in specific patient populations, including critically ill patients, patients with renal impairment or failure, young and old patients, and patients receiving concominant nephrotoxocic drugs such aminoglycosides. In conclusion, determination of serum vancomycin concetrations in the clinical setting and their use­fulness in patient care is questionable and unecessary in the majority of patients.

Αναφορές – References1.
 1. Ingerman M.J., Santoro J.: Vancomycin. A new old agent. Infect. Dis. Clin. North Am. 3: 641-651 (1989)

2. Johnson A.P., Uttler A.E.C., Woodford N., George R.C.: Resis­tance to vancomycin and teicoplanin: An emerging clinical problem. Clin. Microbiol. Rev. 3: 280-291 (1990)

3. Moellering R.C.,Jr, Farber B.F.: Pharmacokinetics of van­comycin. J. Antimicrob. Chemother. 14(Suppl D): 43-45 (1984)

4. Matzke G.R., McGory R.W., Halstenson C.E., Keane W.F.: Pharmacokinetics of vancomycin in patients with vari­ous degrees of renal function. Antimicrob. Agents Che­mother. 25: 433-437 (1984)

5. Cheung P.R.F., Dipiro J.T.: Vancomycin: an update. Pharma­cotherapy 6: 153-165 (1986)

6. Levine J.F.: Vancomycin: A review. Med. Clin. North Am. 71: 1135-1145 (1987)

7. Rotscafer J.C., Crossley K., Zaskar D.E., Mead K., Saw­chuck R.J., Solem L.D.: Pharmacokinetics of vancomycin: Observa­tions in 28 patients and dosage recommendation. Antimicrob. Agents Chemother. 22: 391-394 (1982)

8. Lake K.D., Peterson C.D.: Comparison of vancomycin serum concentrations obtained with standard vs Individual­ized dos­ing regimens. Drug Intell. Clin. Pharm. 19: 549 (Abstract) (1985)

9. Moellering R.C.,Jr, Krogstad D.J., Greenblatt D.J.: Van­comy­cin therapy for patients with impaired renal functions nomo­gram for dosage. Ann. Intern. Med. 94: 343-346 (1981)

10. Matzke G.R., Kovarick J., Ryvack M.J.: Evaluation of the vancomycin clearance: Creatinine-clearance relationship for predicting vancomycin dosage. Clin. Pharm. 4: 311-315 (1984)

11. Ryback M.J., Boike S.C.: Individualized adjustment of van­comycin dosage: Comparison with two dosage mono­grams. Drug Intell. Clin. Pharm. 20: 64-68 (1986)

12. Zokula H.Z., Rotshafer J.C., Cressley K.B., Rodrold K., Pal­ourek F., Fisher F., Riff L.: Evaluation of the Matzke nomo­gram for vancomycin dosing. Paper presented to 26th Inter­science Conference on Antimicrobial Agents and Che­mo­therapy, New Orleans, Louisiana, 1986 Oct. 1, Abstract No 1262

13. Neu H.C.: General concepts on the chemotherapy of in­fec­tious diseases. Med. Clin. North Am. 71: 1051-1064 (1987)

14. Sorrel T.C., Packham D.R., Shanker S.: Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann. Med. 97: 344-348 (1982)

15. Shaad U.B., Mc Cracken G.H., Nelson J.D.: Clinical pharma­cology and efficacy of vancomycin in pediatric pa­tients. J. Pediatr. 96: 119-126 (1980)

16. Lourid D.B., Kaminski T., Burhman J.: Vancomycin in se­vere staphylococcus infections. Arch. Intern. Med. 107: 225-240 (1961)

17. Lisby-Sutch S.M., Nahata M.C.: Dosage guidelines for the use of vancomycin based on its pharmacokinetics in in­fants. Eur. J. Clin. Pharmacol. 35: 637-642 (1988)

18. Cantu T.G., Yamanaka-Yuen N.A., Lietman P.S.: Serum van­comycin concentra­tions: Reappraisal of their clinical value. Clin. Infect. Dis. 18: 533-543 (1994)

19. Woodley D.W., Hall W.H.: The treatment of severe staphy­lococcal infections with vancomycin. Ann. Intern. Med. 55: 235-249 (1961)

20. Cafferkey M.T., Hone R., Keane C.T.: Severe staphylo­coc­cal infections treated with vancomycin. J. Antimicrob. Che­mother. 9: 69-74 (1982)

21. Cony-Makhoul P., Brossard G., Marit G., Bellorgin J.L., Texier-Mangein J., Reiffers J.: A prospective study compar­ing vancomycin and teicoplanin a second-line em­piric ther­apy for infection in neutropenic patients. Br. J. Haemotol. 76 (Suppl 2): 45-40 (1990)

22. Viladrich P.F., Gudiol F., Linares J., Pallares R., Sabate I., Rufic G., Ariza J.: Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob. Agents Che­mother. 35: 2467-2472 (1991)

23. Κα­ρα­χά­λιος Γ.Ν.: Νε­φρο­το­ξι­κό­τη­τα α­πό την χρή­ση της βαν­κο­μυ­κί­νης. Ε­πι­θε­ωρ. Κλιν. Φαρ­μα­κολ. Φαρ­μα­κο­κιν. 8: 175-179 (1990)

24. Farber B.F., Moellering R.C.: Retrospective study of the tox­icity of preparations of vancomycin from 1974 to 1981. Antimicrob. Agents Chemother. 23: 138-141 (1983)

25. Cimino M., Hibbard T., Rotstein C., Slaughter R. Use of pharmacokinetic dosing of vancomycin in combination with an aminoglycoside in granulocytopenic patients. Proceedings in 25th Intersience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, MN: 1985, Sep. 30 (Abstract)

26. Pauly D.J., Muska D.L., Lestico M.R., Lindstrom M.J., Hetsko C.M.: Risk of nephrotoxicity with combination van­comycin-ami­noglycoside antibiotic therapy. Pharmacother­apy 10: 378-382 (1990)

27. Lortholary O., Tod M., Cohen Y., Petijean O.: Aminogly­cosides. Med. Clin. North Am. 79: 761-787 (1995)

28. Baile G.R., Neal D.: Vancomycin ototoxicity and nephro­tox­icity. A review. Med. Toxicol. 3: 376-386 (1988)

29. Brummett R.E.. Ototoxicity of vancomycin and ana­logues. Otolar. Clin. North Am.: 821-828 (1993)

30. Matzke G.R., Zhanel G.G., Guay D.R.P.: Clinical phar­macoki­netics of vancomycin. Clin. Pharmacokinet 11: 257-282 (1986)

31. Kirby W.M.M., Perry D.M., Bauer A.W.: Treatment of staphy­lococcal septicemia with vancomycin: report of thirty-three cases. N. Engl. J. Med. 262: 49-55 (1960)

32. Morris A.J., Blinsky R.T.: Prevention of staphylococcal in­fections by continuous vancomycin prophylaxis. Am. J. Med. Sci. 262: 87-92 (1971)

33. Odio C., McCracken G.H., Nelson J.D.: Nephrotoxicity as­sociated with vancomycin-aminoglycoside therapy in four chil­dren. J. Pediatr. 105: 491-493 (1984)

34. Mellor J.A., Kingdom J., Cafferkey M., Keane C.T.: Van­comycin ototoxicity in patients with normal renal func­tion. Br. J. Audiol. 18: 179-180 (1984)

35. Mellor J.A., Kingdom J., Calter Key M., Keame C.T.: Vancomycin toxicity: a prospective study. J. Antimicrob. Chemother. 15: 775-780 (1985)

36. Cantri T.G., Yamanaka-Yuen N.A., Leitman P.S.: Serum vancomycin concentrations: Reappraisal of their clinical value. Clin. Infect. Dis. 18: 53-543 (1994)

37. Leader W.C., Chandler M.H.H., Castiglia M.: Pharma­coki­netic optimisation of vancomycin therapy. Clin. Pharma­cokinet. 28: 327-342 (1995)

38. Geraci J.E., Hellman F.R., Nickols D.R.: Some Labora­tory and clinical experience with a new antibiotic vancomy­cin. Antib. Ann. 1: 90-106 (1957)

39. Zeckel M.L., Woodworth J.R.: Vancomycin: A clinical overview. In: (R. Nagarajan, ed.) Glycopeptide Antibiotics. Pp. 309-412, Marcel Dekker, New York, 1994

40. Pryka R.D., Rodvold K.A., Erdman S.M.: An update compari­son of drug dosing methods, Part IV: Vancomycin. Clin. Pharmacokinet. 20: 463-476 (1991)

41. Moellering R.C.,Jr: Editorial: Monitoring serum vancomy­cin levels: Climbing the mountain because it is time? Clin. Infect. Dis. 18: 544-546 (1994)

42. Healy D.P., Polk R.E., Carson M.L., Rock D.T., Com­stock T.J.: Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antim­icrob. Agents Chemother. 31: 393-397 (1987)

43. Rodvold K.A., Blun R.A., Fischer J.H., Zokufa H.Z., Rotschafer J.C., Crosslex K.B., Riff L.J.: Vancomycin pharma­cokinetics in patients with various degree of renal function. Antimicrob. Agents Chemother. 321: 848-852 (1988)

44. Shaad V.B., Mc Cracken C.H. Nelson J.D.: Clinical Pharma­cology and efficacy of vancomycin in pediatric pa­tients. J. Pediatr. 96: 119-126 (1980)

45. Rybak M.J., Albrecht L.M., Berman J.R., Warbasse L.H., Svensson C.K.: Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob. Agents Che­mother. 34: 792-795 (1990)

46. Guay D.R.P., Vance-Bryan K., Gililand S.S.: Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster. J. Clin. Pharma­col. 33: 918-922 (1993)

47. Vance-Bryan K., Guay D.R.P., Gililand S.S.: Effects of obesity on vancomycin pharmacokinetic parameters as de­termined by using a Bayesian forecasting technique. Antimi­crob. Agents Chemother. 37: 436-440 (1993)

48. Rodvold K.A., Zokufa H., Rotschafer J.C.: Routine monitor­ing of serum vancomycin concentrations: Can wait­ing be justified? Clin. Pharm. 6: 655-658 (1987)

49. Edward D.J.: Routine monitoring of serum vancomycin concentrations: waiting for proof of its value. Clin. Pharm. 6: 652-654 (1987)

50. Freeman C.D., Quintiliani R., Nightingale C.H.: Van­comycin therapeutic drug monitoring: Is it necessary? Ann. Pharma­cother. 27: 594-599 (1993)

51. Geraci J.E.: Vancomycin. Mayo Clin. Proc. 52: 631-634 (1979)

52. Saunders N.J.: Why monitor peak vancomycin concen­tra­tions?  Lancet 344: 1748-1750 (1994)

Online ISSN 1011-6575

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
• Chemical Abstracts

• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor

Articles published in this Journal are Indexed or Abstracted in:
• Chemical Abstracts
• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor

Άρθρα Δημοσιευμένα στην Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση
Articles Published in Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Συντακτικη Επιτροπή-Editorial Board

ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ – ANNUAL SUBSCRIPTION
Γλώσσα Πλήρους Κειμένου –
Full Text Language
Ελληνικά – Greek
Παραγγελία – Αγορά –
Order – Buy
Ηλεκτρονική Μορφή: pdf (70 €) –
Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr
Έντυπη Μορφή (70 € + έξοδα αποστολής)
Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr

 

Προσθέστε στους σελιδοδείκτες το μόνιμο σύνδεσμο.

Τα σχόλια είναι απενεργοποιημένα.